{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T02:25:54Z","timestamp":1767925554310,"version":"3.49.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.clml.2011.10.004","type":"journal-article","created":{"date-parts":[[2011,12,10]],"date-time":"2011-12-10T23:34:20Z","timestamp":1323560060000},"page":"88-93","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Managing Chronic Myeloid Leukemia: A Coordinated Team Care Perspective"],"prefix":"10.1016","volume":"12","author":[{"given":"Stacie","family":"Holloway","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharine","family":"Lord","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beverly","family":"Bethelmie-Bryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marian W.","family":"Shepard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Neely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morgan","family":"McLemore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satyanarayan K.","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aldemar","family":"Montero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William S.","family":"Jonas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara Pierson","family":"Gladney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shyam L.","family":"Khanwani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silpa C.","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anup K.","family":"Lahiry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard T.","family":"Heffner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elliott","family":"Winton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha","family":"Arellano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna Jean","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2011.10.004_bib1","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.10.004_bib2","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.10.004_bib3","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.10.004_bib4","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis","volume":"26","author":"de Lavallade","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.10.004_bib5","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.10.004_bib8","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy","volume":"109","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.004_bib9","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.004_bib11","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1002\/cncr.24325","article-title":"Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia","volume":"115","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2011.10.004_bib12","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/jncimonographs\/lgq010","article-title":"The organization of multidisciplinary care teams: modeling internal and external influences on cancer care quality","volume":"2010","author":"Fennell","year":"2010","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"suppl 5","key":"10.1016\/j.clml.2011.10.004_bib13","doi-asserted-by":"crossref","first-page":"v165","DOI":"10.1093\/annonc\/mdq201","article-title":"Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Baccarani","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2011.10.004_bib14","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.10.004_bib15","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2010-10-309807","article-title":"Poor adherence is the main reason for loss of CCyR and imatinib failure for CML patients on long term therapy","volume":"117","author":"Ibrahim","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.004_bib16","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1600-0609.2007.01021.x","article-title":"Peripheral blood cytogenetic studies in hematological neoplasms: predictors of obtaining metaphases for analysis","volume":"80","author":"Hussein","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2011.10.004_bib17","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1159\/000046635","article-title":"Cytogenetic and molecular monitoring of residual disease in chronic myeloid leukaemia","volume":"107","author":"Kaeda","year":"2002","journal-title":"Acta Haematol"},{"key":"10.1016\/j.clml.2011.10.004_bib18","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/cncr.25678","article-title":"Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond","volume":"117","author":"Lima","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2011.10.004_bib19","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1365-2141.1999.01749.x","article-title":"Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics","volume":"107","author":"Branford","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2011.10.004_bib20","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1182\/blood-2009-02-163485","article-title":"How I monitor residual disease in chronic myeloid leukemia","volume":"114","author":"Radich","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.004_bib21","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.004_bib22","first-page":"160","article-title":"Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia","volume":"9","author":"Kantarjian","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2011.10.004_bib23","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3324\/haematol.11910","volume":"93","author":"Lundan","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2011.10.004_bib24","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1182\/blood.V87.4.1549.bloodjournal8741549","article-title":"Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction","volume":"87","author":"Hochhaus","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.10.004_bib25","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.10.004_bib26","series-title":"Gleevec (imatinib mesylate)","year":"2010"},{"key":"10.1016\/j.clml.2011.10.004_bib27","series-title":"Tasigna (nilotinib)","year":"2011"},{"key":"10.1016\/j.clml.2011.10.004_bib28","series-title":"Sprycel (dasatinib)","year":"2010"},{"key":"10.1016\/j.clml.2011.10.004_bib29","doi-asserted-by":"crossref","first-page":"5112","DOI":"10.1002\/cncr.26149","article-title":"Do multidisciplinary team meetings make a difference in the management of lung cancer?","volume":"117","author":"Boxer","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2011.10.004_bib30","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.3748\/wjg.v17.i15.2013","article-title":"Effect of multidisciplinary team treatment on outcomes of patients with gastrointestinal malignancy","volume":"17","author":"Du","year":"2011","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.clml.2011.10.004_bib31","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1200\/JOP.2010.000036","article-title":"Cancer Portal Project: a multidisciplinary approach to cancer care among Hispanic patients","volume":"7","author":"Gany","year":"2011","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.clml.2011.10.004_bib32","first-page":"394","article-title":"An ethnographic investigation tracking the experience of chronic myeloid leukemia (CML) patients on tyrosine kinase inhibitor (TKI) therapies","volume":"116","author":"Guilhot","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.clml.2011.10.004_bib33","article-title":"Predictors of cancer information overload: findings from a national survey","volume":"12","author":"Kim","year":"2007","journal-title":"Inf Res"},{"key":"10.1016\/j.clml.2011.10.004_bib34","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1073\/pnas.0510423103","article-title":"Gene expression changes associated with progression and response in chronic myeloid leukemia","volume":"103","author":"Radich","year":"2006","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011005805?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011005805?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:23:09Z","timestamp":1761870189000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265011005805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S2152265011005805"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2011.10.004","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Managing Chronic Myeloid Leukemia: A Coordinated Team Care Perspective","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2011.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}